Trial · NCT03964506
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
NCT03964506, Early phase 1, Recruiting, Omar Aljitawi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant. Trials, record NCT03964506. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03964506
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
- NCT number
- NCT03964506
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Omar Aljitawi
- Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Chronic Monocytic Leukemia, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm
- Interventions
- Hyperbaric oxygen
- First posted
- 2019-05-28
- Last updated
- 2026-06-03
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Immediate safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplantation in Cohort 1 | 24 hours | Treatment-limiting toxicities will be assessed 24-hours post-hyperbaric oxygen therapy. |
| Primary | Immediate safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplantation in cohort 2 | 24 hours | Treatment-limiting toxicities will be assessed 24-hours post-hyperbaric oxygen therapy. |
| Primary | Long term safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplant in Cohort 1 | 100 days | Possible long-term effects of hyperbaric oxygen therapy treatment prior to allogeneic peripheral blood stem cell transplant will be assessed at day +100 post-transplant |
| Primary | Long term safety of hyperbaric oxygen therapy prior to allogeneic stem cell transplant in Cohort 2 | 100 days | Possible long-term effects of hyperbaric oxygen therapy treatment prior to allogeneic peripheral blood stem cell transplant will be assessed at day +100 post-transplant |
| Secondary | Time to neutrophil recovery in Cohort 1 | 100 days | based on the patient having achieved three consecutive days of Absolute Neutrophile Count (ANC) ≥ 500/microliter |
| Secondary | Time to neutrophil recovery in Cohort 2 | 100 days | based on the patient having achieved three consecutive days of Absolute Neutrophile Count (ANC) ≥ 500/microliter |
| Secondary | Time to complete donor chimerism in Cohort 1 | 100 days | Bone marrow chimerism will be checked on day +30 and day +100 Bone Marrow (BM) samples according to our standard of care |
| Secondary | Time to complete donor chimerism in Cohort 2 | 100 days | Bone marrow chimerism will be checked on day +30 and day +100 Bone Marrow (BM) samples according to our standard of care |
| Secondary | Incidence of mucositis in Cohort 1 | 100 days | |
| Secondary | Incidence of graft versus host disease in Cohort 1 | 100 days |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03964506
GET https://conductscience.org/api/trials/v1/NCT03964506/registered